Sparks NV, February 13, 2023: Ludwig Enterprises (OTC: LUDG), developers of mRNA Inflammatory Index™(Patent Pending) and producers of NuGenea the anti-inflammatory nutraceutical is pleased to announcethat it has entered into an agreement with The Fannon Group, to provide healthcare sales and marketing leadership as they launchtheir flagship products towards the end of Q1 2023.
“The Fannon Group and its CEO Luke is a great addition to the team,” said Anne Blackstone President of Ludwig Enterprises. “Luke and his team’sexpertise in healthcare sales and marketing will help ensure a successful launch of our products.”
Founded in 2005 The Fannon Group has helped hundreds of healthcare organizations grow revenue and profitability. Luke Fannon, CEO of the Fannon Group, has over 30 years of experience in healthcare sales and marketing including over 10 years of c-suite leadership roles.
“I am truly excited to be part of the Ludwig Team,” commented Mr. Fannon. “The mRNA Inflammatory Index™ and NuGenea have tremendous opportunity to do something never before accomplished in the field healthcare –potentially identify sources of chronic inflammation while creating the chance to prevent chronic illnesses from developing.”
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer.NuGenea, a scientifically formulated nutraceutical supported by decades of research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary My RNA for Life™.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig’s innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in cost. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiary Precision Genomics is poised to significantly impact how we think about disease and live longer healthier lives. For more info please go to: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Precision Genomics & Ludwig Enterprises Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
For Scientific Related Inquiries
Dr. Marvin S. Hausman MD
Chief Science Officer
503-327-4173
[email protected]
For Business Related Inquiries
Luke J. Fannon
484-429-5846
[email protected]
Ludwig Enterprises, Inc.
Anne Blackstone,
786-235-9026
www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.